tional based assay system developed by Liu et al. 8 We found that granulocytes were polyclonal at the time that the JAK2V617F was undetectable (Figure 1b) . Furthermore, 4 months after discontinuation of Peg-rIFN-a, a monoclonal pattern of the hematopoiesis was again documented, which corresponded with the increased percentage of JAK2V617F (Figure 1b) . Although Peg-rIFN-a is effective in decreasing the malignant clone, the discontinuation of this agent resulted in the reappearance of JAK2V617F and reestablishment of clonal hematopoiesis. These studies indicate that intermittent therapy with this agent might be suboptimal for eliminating the malignant clone in PV and that low-dose uninterrupted therapy with Peg-rIFN-a might be required for these purposes. Further studies are clearly warranted to investigate the optimal dose and the schedule of Peg-rIFN-a to eliminate the malignant clone in PV and to determine if such an approach alters the natural history of this disorder.
Epigenetic regulation of brain expressed X-linked-2, a marker for acute myeloid leukemia with mixed lineage leukemia rearrangements Leukemia (2007) Human brain expressed X-linked (BEX) is a novel gene family consisting of at least six family members. 1 Human BEX1 and BEX2 are highly expressed in various brain-derived tissues, but show diverse expression patterns in peripheral tissues like the liver or pancreas. [1] [2] [3] We identified BEX2 (previously named BEX1) as candidate gene for the diagnosis of acute myeloid leukemia (AML) with mixed lineage leukemia (MLL) translocations. 3 A similar correlation between MLL status and gene expression had been described for HOX genes: acute Letters to the Editor leukemia cells carrying rearrangements of the MLL gene show high expression levels of HOXA9 and the HOX cofactor MEIS1. 4, 5 Reciprocal MLL translocations occur mostly in infant acute lymphoblastic leukemia and secondary AML. Both, cytoplasmic and nuclear genes are found as MLL fusion partners, replacing C-terminal MLL sequences. More than three dozen MLL fusions have been described, but it is a limited number (MLL-AF4, MLL-AF9, MLL-ENL, MLL-AF10 and MLL-ELL) that accounts for the majority of clinical cases. All five MLL partners listed encode for nuclear proteins. According to the current view, these genes convert the fusion proteins into potent transactivators, whereas the N-terminal MLL part is responsible for target binding. 6 Highlevel expression of MLL-targeted HOX genes may then contribute to leukemogenesis. 6 We have recently shown that MLL mutant (MLLmu) leukemia cells are not only characterized by a high-level expression of HOX genes, but that also BEX2 is overexpressed in MLLmu AML. 3, 5 In healthy individuals, BEX2 is expressed in the brain, the pancreas and testis, but not in hematopoetic cells. The specific expression in MLLmu AML makes BEX2 a candidate gene for the diagnosis of MLLmu AML. 3 Correlation between BEX2 expression and MLL chromosomal aberration in the cell lines used in this study is shown in Figure 1 . We were interested to find out whether the BEX2 expression in these cell lines is regulated by epigenetic mechanisms. BEX1 and BEX2 have recently been described as epigenetically controlled candidate tumor suppressor genes in malignant glioma. 7 In epigenetically regulated genes, methylcytosine-phosphate-guanosine (CpG) recognizing proteins like MeCP2 may bind to methylated CpG-rich areas and contribute to silencing of these genes by recruiting histone deacetylases (HDAC) and histone methyltransferases, enzymes that eventually provoke a repressive chromatin state. 8, 9 The 5 0 region of BEX2 including exon 1 and exon 2 contains a CpG-rich region with 65 potential methylation sites ( Figure 2a) . Both, the HDAC inhibitor trichostatin A (TSA) and the demethylating agent 5-Aza-2 0 deoxycytidine (Aza) substantially increased the expression of BEX2 mRNA in MLL wild-type (MLLwt) cells, thus supporting the notion of BEX2 as an epigenetically regulated gene ( Figure 3) .
To further verify whether BEX2 expression levels were correlated with the methylation status of BEX2 5 0 CpG islands, we performed a bisulfide conversion assay with MLLmu and MLLwt cell lines. The results showed a strong correlation between MLL aberration, BEX2 expression and hypomethylation of the 5 0 BEX2 region (Table 1 ). In contrast, MLLwt BEX2-negative cell lines exhibited hypermethylation of this CpG island (Table 1) . This correlation between methylation status and BEX2 expression was especially pronounced in the region directly upstream of exon 1 of BEX2, with 90% methylation in the MLLwt, and 5% methylation in MLLmu cell lines (Figure 2a  and b) .
Histone acetylation is a second important chromatin regulating mechanism besides DNA methylation. Hyperacetylation of histones has been associated with increased transcription. 9 Treatment of MLLwt BEX2-negative cells with the HDAC inhibitor TSA lead to a marked increase in BEX2 expression (Figure 3) . Also chromatin immunoprecipitation (ChiP) analyses supported the view that histone acetylation plays a role in BEX2 regulation: immunoprecipitation of acetylated histone H3 coprecipitated chromatin from the 5 0 part of BEX2 in MLLmu, but not in MLLwt cells (Figure 4) .
Our results suggest that the expression of BEX2, a candidate gene for the diagnosis of MLLmu AML, is regulated by epigenetic mechanisms. MLLwt AML cells do not express 
Figure 4
ChIP assay using anti-acetylated histone H3 antibody. (a) BEX2 regions tested for interaction with acetylated histone H3. Primer pairs used to detect DNA coprecipitating with acetylated histone H3 are listed in Table 1 Few investigations to date into involvement of non-haematopoietic stromal cells (nHSCs) in haematological malignancies have provided divergent results. 1 Although one report has demonstrated that nHSC do not participate in chronic myeloid leukaemia (Keating et al., Blood 1986; 68: 1449, abstract), a study of patients with myeloproliferative disorders that were heterozygous for glucose-6-phosphate dehydrogenase showed that nHSC from adherent layers of long-term marrow cultures derived from the same clonal progenitors as the multipotent stem cell disorder.
2 Furthermore, we recently described a cell line from a patient with acute lymphoblastic leukaemia that concomitantly exhibited markers of nHSC and of haematopoie- Table 1 Immunophenotypic and molecular analysis of nHSC from 20 patients with cMPDs Abbreviations: AR, % of V617F mutated allele; ET, essential thrombocythemia; IM, idiopathic myelofibrosis; LLME, leucyl-leucine methyl ester; PV, polycythemia vera.
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